骨科

订阅

MedSci主页 / 所有栏目 / 骨科

Mol Med Rep：功能性β-磷酸三钙可用作组织工程和再生医学中的理想支架

2019-07-28 不详 网络

关注

间充质干细胞（MSC）通常用于整形外科组织工程，骨髓来源的间充质干细胞（BMSCs）目前被认为是金标准。基于MSC的组织工程治疗中最重要的问题之一是病理组织中MSC的数量较少。在体内实现MSC向缺陷或受损组织的有效募集是一大难题。本研究旨在构建一种能够有效募集骨髓间充质干细胞以促进病理组织修复的生物材料。使用通过吸附/冷冻干燥策略吸附在β-TCP上的BMSC亲和肽DPIYALSWSGMA（DPI）

间充质干细胞（MSC）通常用于整形外科组织工程，骨髓来源的间充质干细胞（BMSCs）目前被认为是金标准。基于MSC的组织工程治疗中最重要的问题之一是病理组织中MSC的数量较少。在体内实现MSC向缺陷或受损组织的有效募集是一大难题。本研究旨在构建一种能够有效募集骨髓间充质干细胞以促进病理组织修复的生物材料。

使用通过吸附/冷冻干燥策略吸附在β-TCP上的BMSC亲和肽DPIYALSWSGMA（DPI）合成功能性β-磷酸三钙（β-TCP）。将C57BL/6小鼠来源的BMSC接种到DPI肽修饰的β-TCP（β-TCP-DPI）上。体外实验表明，与未修饰的β-TCP相比，β-TCP-DPI增强了BMSC的粘附和增殖。

总之，本研究的结果表明，功能性β-TCP可用作组织工程和再生医学中的理想支架。

原始出处：

Wang G, Man Z, et al., Enhanced adhesion and proliferation of bone marrow mesenchymal stem cells on β tricalcium phosphate modified by an affinity peptide. Mol Med Rep. 2019 Jan;19(1):375-381. doi: 10.3892/mmr.2018.9655. Epub 2018 Nov 13.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1915511, encodeId=2c0b191551144, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Apr 02 04:11:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801451, encodeId=f21b180145186, content=<a href='/topic/show?id=b89ae38472d' target=_blank style='color:#2F92EE;'>#磷酸三钙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73847, encryptionId=b89ae38472d, topicName=磷酸三钙)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Aug 15 15:11:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417200, encodeId=3085141e200c2, content=<a href='/topic/show?id=8b72e769056' target=_blank style='color:#2F92EE;'>#组织工程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77690, encryptionId=8b72e769056, topicName=组织工程)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f3243688, createdName=zhu_jun9838, createdTime=Tue Jul 30 11:11:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609891, encodeId=aaa316098917b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 30 11:11:00 CST 2019, time=2019-07-30, status=1, ipAttribution=)]
    2020-04-02 xlxchina

    #功能性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1915511, encodeId=2c0b191551144, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Apr 02 04:11:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801451, encodeId=f21b180145186, content=<a href='/topic/show?id=b89ae38472d' target=_blank style='color:#2F92EE;'>#磷酸三钙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73847, encryptionId=b89ae38472d, topicName=磷酸三钙)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Aug 15 15:11:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417200, encodeId=3085141e200c2, content=<a href='/topic/show?id=8b72e769056' target=_blank style='color:#2F92EE;'>#组织工程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77690, encryptionId=8b72e769056, topicName=组织工程)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f3243688, createdName=zhu_jun9838, createdTime=Tue Jul 30 11:11:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609891, encodeId=aaa316098917b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 30 11:11:00 CST 2019, time=2019-07-30, status=1, ipAttribution=)]
    2019-08-15 医者仁心

    #磷酸三钙#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1915511, encodeId=2c0b191551144, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Apr 02 04:11:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801451, encodeId=f21b180145186, content=<a href='/topic/show?id=b89ae38472d' target=_blank style='color:#2F92EE;'>#磷酸三钙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73847, encryptionId=b89ae38472d, topicName=磷酸三钙)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Aug 15 15:11:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417200, encodeId=3085141e200c2, content=<a href='/topic/show?id=8b72e769056' target=_blank style='color:#2F92EE;'>#组织工程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77690, encryptionId=8b72e769056, topicName=组织工程)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f3243688, createdName=zhu_jun9838, createdTime=Tue Jul 30 11:11:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609891, encodeId=aaa316098917b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 30 11:11:00 CST 2019, time=2019-07-30, status=1, ipAttribution=)]
    2019-07-30 zhu_jun9838

    #组织工程#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1915511, encodeId=2c0b191551144, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Apr 02 04:11:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801451, encodeId=f21b180145186, content=<a href='/topic/show?id=b89ae38472d' target=_blank style='color:#2F92EE;'>#磷酸三钙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73847, encryptionId=b89ae38472d, topicName=磷酸三钙)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Aug 15 15:11:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417200, encodeId=3085141e200c2, content=<a href='/topic/show?id=8b72e769056' target=_blank style='color:#2F92EE;'>#组织工程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77690, encryptionId=8b72e769056, topicName=组织工程)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f3243688, createdName=zhu_jun9838, createdTime=Tue Jul 30 11:11:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609891, encodeId=aaa316098917b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 30 11:11:00 CST 2019, time=2019-07-30, status=1, ipAttribution=)]
    2019-07-30 ms3994565386320060

    #Med#

    0